Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1003 studies found for:    "Bacterial Infections" | United States
Show Display Options
Rank Status Study
1 Recruiting Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With Known or Suspected Bacterial Infection
Condition: Bacterial Infections
Intervention: Drug: Dalbavancin
2 Completed A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
Condition: Bacterial Infections
Interventions: Drug: Placebo IV Solution;   Drug: Debio 1450 IV Solution;   Drug: Placebo Tablet or Capsule;   Drug: Debio 1450 Tablet;   Drug: Debio 1450 Capsule;   Drug: Debio 1450 Oral Solution;   Drug: Pantoprazole
3 Completed A Single Dose Study of Debio 1450 in Healthy Subjects
Condition: Bacterial Infections
Interventions: Drug: Debio 1450;   Drug: Placebo
4 Completed Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
Condition: Bacterial Infection
Intervention: Drug: TR-701 FA
5 Completed Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria
Condition: Bacterial Infection
Intervention:
6 Recruiting VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
Condition: Bacterial Infections
Interventions: Drug: VNRX-5133;   Drug: Placebo
7 Active, not recruiting Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
Condition: Bacterial Infections
Intervention: Device: BestDose Computer Software
8 Completed Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
Condition: Bacterial Infections
Interventions: Drug: TR-701 FA for injection, 200 mg/vial;   Drug: TR-701 FA tablets
9 Recruiting Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Condition: Bacterial Infections
Intervention:
10 Completed Evaluation of Atuna Racemosa Toxicity
Condition: Bacterial Infections
Intervention: Drug: Atuna Racemosa
11 Recruiting An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years
Condition: Gram-Positive Bacterial Infections
Intervention: Drug: Telavancin
12 Active, not recruiting Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates
Condition: Gram-negative Bacterial Infections
Intervention:
13 Active, not recruiting Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Condition: Gram-negative Bacterial Infections
Intervention:
14 Active, not recruiting Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
Condition: Bacterial Infections and Mycoses
Intervention:
15 Completed Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
Conditions: Bacterial Infections;   Group B Streptococcus
Interventions: Biological: GBS III-TT-SSI;   Biological: GBS III-TT-MPHL
16 Completed Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms
Condition: Bacterial Infection
Intervention: Other: No intervention
17 Recruiting Gram Negative Bacteremia, Risk Factors for Failure of Therapy
Condition: Gram-Negative Bacterial Infections
Intervention:
18 Completed
Has Results
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Condition: Gram-Positive Bacterial Infections
Interventions: Drug: Telavancin;   Drug: Vancomycin, nafcillin, oxacillin, or cloxacillin
19 Completed Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
Condition: Bacterial Infections
Intervention: Drug: Dalbavancin
20 Active, not recruiting Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods
Conditions: Bacterial Infection;   Clostridium Difficile
Intervention: Other: Educational Intervention

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.